| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
|
|
|||||||||
|
|
Oncology-Clinical Diagnosis: Hematologic TumorsHematology Malignancy |
1 Nuclear Medicine, Yeditepe University Hospital, Istanbul, Turkey; 2 Nuclear Medicine, Euromed Imaging Center, Istanbul, Turkey; 3 Radiology, Bakirkoy Goverment Hospital, Istanbul, Turkey; 4 Internal Medicine Division of Oncology, Yediyepe University Hospital, Istanbul, Turkey
1429
Objectives: The aim of this study was to evaluate the predictive value of sequential PET before and after HDT and ASCT in Hodgkin (HL) and Non Hodgkin lymphoma (NHL).
Methods: We studied 20 lymphoma patients,9 patients with NHL and 11 patients with HL. There were 10 male and 10 female patients aged between 12 and 65 years (mean 34.58). A pretreatment PET/CT was performed for all patients (PET0, CT0). Follow-up scans were performed on 30th (PET1, CT1), 60th (PET2, T2), 100th days (PET3, CT3). The mean follow-up period was 12 months (range 6-18 months). PET and CT scans were retrospectively blindly evaluated by a nuclear medicine and radiology physicians.
Results: PET and CT scans were positive for all patients before HDT/ASCT. PET1 and PET2 scans were positive for 8 patients, PET3 scans were positive for 6 patients. 30th, 60th and 100th day CT scans were positive for 10, 8 and 5 patients, respectively. At the end of 1st year 4 patients died whose PET scans were positive. 12 patients of 20 had negative PET scans confirming CR while 8 patients had negative CT scans. Six patients had still positive CT scans. Two of these 6 patients had positive scan and relapsed. After one year, overall survival and progression free survivals were 100% and 91%, respectively. All results were correlated with clinics and follow up.
Conclusions: Our study suggested PET had a higher prognostic value than CT in refractory lymphoma and should be performed as a more valid alternative for post-treatment evaluation.
| ||||||||||||||||||||||||||||||||||||||
